MRK1

111.6

+0.36%↑

SHL.DE

46.45

+0.13%↑

ARGX

489.5

-0.61%↓

FRE

40.98

-0.07%↓

ONC.US

298.95

+1.5%↑

MRK1

111.6

+0.36%↑

SHL.DE

46.45

+0.13%↑

ARGX

489.5

-0.61%↓

FRE

40.98

-0.07%↓

ONC.US

298.95

+1.5%↑

MRK1

111.6

+0.36%↑

SHL.DE

46.45

+0.13%↑

ARGX

489.5

-0.61%↓

FRE

40.98

-0.07%↓

ONC.US

298.95

+1.5%↑

MRK1

111.6

+0.36%↑

SHL.DE

46.45

+0.13%↑

ARGX

489.5

-0.61%↓

FRE

40.98

-0.07%↓

ONC.US

298.95

+1.5%↑

MRK1

111.6

+0.36%↑

SHL.DE

46.45

+0.13%↑

ARGX

489.5

-0.61%↓

FRE

40.98

-0.07%↓

ONC.US

298.95

+1.5%↑

Search

Sanofi SA

Atidarymo kaina

SektoriusSveikatos priežiūra

83.32 0.06

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

83.05

Max

83.79

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.4B

1.9B

Pardavimai

3B

11B

P/E

Sektoriaus vid.

16.742

39.857

Pelnas, tenkantis vienai akcijai

1.79

Dividendų pajamingumas

4.77

Pelno marža

17.65

Darbuotojai

82,878

EBITDA

2.2B

2.8B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+33.66% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

4.77%

2.42%

Kitas uždarbis

2025-07-31

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-28B

102B

Ankstesnė atidarymo kaina

83.26

Ankstesnė uždarymo kaina

83.32

Naujienos nuotaikos

By Acuity

36%

64%

125 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Sanofi SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-01 19:16; UTC

Įsigijimai, susijungimai, perėmimai

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

2025-07-01 12:03; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

Adagene ADRs Rise Following Sanofi Investment

2025-06-30 14:30; UTC

Įsigijimai, susijungimai, perėmimai

Santander Submits Binding Offer for Sabadell's TSB Unit, Reuters Says, Citing Sources

2025-06-19 07:27; UTC

Įsigijimai, susijungimai, perėmimai

Barclays, Santander Interested in Sabadell's U.K. Unit TSB, Bloomberg Says, Citing Sources

2025-06-11 08:25; UTC

Įsigijimai, susijungimai, perėmimai

EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio

2025-06-02 16:05; UTC

Pagrindinės rinkos jėgos

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

2025-07-09 10:59; UTC

Rinkos pokalbiai

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

2025-07-09 09:17; UTC

Karštos akcijos

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

2025-07-07 12:06; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Santander's TSB Purchase Should Help Improve U.K. Risk Profile -- Market Talk

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Received All Required Authorizations

2025-07-04 15:48; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

2025-07-04 15:47; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Agreement Was Announced on Dec. 19

2025-07-04 15:47; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

2025-07-04 15:46; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

2025-07-03 08:25; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

BBVA Challenged With Enticing Enough Sabadell Shareholders to Support Takeover -- Market Talk

2025-07-03 07:03; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Sabadell's TSB Sale Doesn't Alter Strategic Rationale for BBVA Bid -- Market Talk

2025-07-02 11:59; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Santander's TSB Purchase to Help Solve U.K. Profitability Drag -- Market Talk

2025-07-02 11:48; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Spanish Banks in M&A Triangle Over TSB Deal -- Market Talk

2025-07-02 06:08; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Sabadell's TSB Sale to Santander Is Win-Win Deal -- Market Talk

2025-07-02 05:34; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Santander's Acquisition of Sabadell's TSB Is Somewhat Surprising -- Market Talk

2025-07-01 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

2025-07-01 16:55; UTC

Uždarbis

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

2025-06-27 09:13; UTC

Rinkos pokalbiai

Santander Is Cheap and Has Catalysts Ahead -- Market Talk

2025-06-20 08:36; UTC

Rinkos pokalbiai

Predictability of U.K. Banks Has Value -- Market Talk

2025-06-20 07:10; UTC

Rinkos pokalbiai

Strong Correction Unlikely for Spanish Banks -- Market Talk

2025-06-10 12:18; UTC

Uždarbis

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

2025-06-02 13:50; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2025-06-02 12:33; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sanofi SA Prognozė

Kainos tikslas

By TipRanks

33.66% į viršų

12 mėnesių prognozė

Vidutinis 111.203 EUR  33.66%

Aukščiausias 127 EUR

Žemiausias 95 EUR

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sanofi SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

16 ratings

11

Pirkti

5

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

91.3 / 96.1Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

125 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.